Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis

References

• Angelopoulos J, Krassakopoulos N, Nathanson R, et al. Co-administration of ezetimibe and a statin in management of dyslipidemias: A meta-analysis of clinical trials. Arch Med Sci 2009;5:363
   Web of Science ®Google Scholar
• Murdoch D, Scott LJ. Ezetimibe/simvastatin: a review of its use in the management of hypercholesterolemia. Am J Cardiovasc Drugs 2004;4:405-22
   PubMedGoogle Scholar
• National Institutes of Health NHLaBI. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/upd-info_prof.htm [Last accessed November 2010]
   Google Scholar
• Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006;47:2130-9
   PubMed Web of Science ®Google Scholar
• Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Can J Cardiol 2009;25:567-79
   PubMed Web of Science ®Google Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10:S1-S10
   PubMed Web of Science ®Google Scholar
• National Institute for health and clinical excellence. CG67 Lipid modification: full guideline. Available at: http://www.nice.org.uk/nicemedia/live/11982/40742/40742.pdf [Last accessed November 2010]
   Google Scholar
• Toutouzas K, Drakopoulou M, Skoumas I, et al. Advancing therapy for hypercholesterolemia. Expert Opin Pharmacother 2010;11:1659-72
   PubMed Web of Science ®Google Scholar
• Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm 2008;14:S3-28
   PubMed Web of Science ®Google Scholar
• Daskalopoulou SS, Mikhailidis DP. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr Med Res Opin 2006;22:511-28
   PubMed Web of Science ®Google Scholar
• Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67
   PubMed Web of Science ®Google Scholar
• Gagne C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084–91
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS. Ezetimibe: a new addition to lipid–lowering therapy. Int J Clin Pract 2003;57:653-5
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:2009-26
   PubMed Web of Science ®Google Scholar
• McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007;192:432-7
   PubMed Web of Science ®Google Scholar
• Cook JR, Yin D, Alemao E, et al. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway. Pharmacoeconomics 2004;22(Suppl. 3):49-61
   PubMed Web of Science ®Google Scholar
• Thomson Dialog. DataStar Web. Available at: www.datastarweb.com [Last accessed 4 March 2010]
   Google Scholar
• The Cochrane Library. Cochrane Database of Systematic Reviews. Available at: www.mrw.interscience.wiley.com/cochrane/cochrane_clsysrev_subjects_fs.html [Last accessed November 2010]
   Google Scholar
• Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. Available at: http://www.cochrane-handbook.org [Last accessed November 2010]
   Google Scholar
• Cochran W. The combination of estimates from different experiments. Biometrics 1954;10:101-29
   Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88
   PubMed Web of Science ®Google Scholar
• National Coordinating Centre for Health Technology Assessment. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation (Structured abstract). Health Technology Assessment 2008;12:232
   Web of Science ®Google Scholar
• Kashani A, Sallam T, Bheemreddy S, et al. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am J Cardiol 2008;101:1606-13
   PubMed Web of Science ®Google Scholar
• Sharma M, Ansari MT, Bou-Setta AM, et al. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med 2009;151:622-30
   PubMed Web of Science ®Google Scholar
• Catapano A, Brady WE, King TR, et al. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Curr Med Res Opin 2005;21:1123-30
   PubMed Web of Science ®Google Scholar
• Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol 2007;49:2003-9
   PubMed Web of Science ®Google Scholar
• Fichtlscherer S, Schmidt LC, Bojunga S, et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for ‘pleiotropic’ functions of statin therapy. Eur Heart J 2006;27:1182-90
   PubMed Web of Science ®Google Scholar
• Gagné C, Gaudet D, Bruckert E, Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002;105:2469-75
   PubMed Web of Science ®Google Scholar
• Robinson JG, Ballantyne CM, Grundy SM, et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET Study). Am J Cardiol 2009;103:1694-702
   PubMed Web of Science ®Google Scholar
• Gaudiani LM, Lewin A, Meneghini L, et al. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes Metab 2005;7:88-97
   PubMed Web of Science ®Google Scholar
• Reckless JP, Henry P, Pomykaj T, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int J Clin Pract 2008;62:539-54
   PubMed Web of Science ®Google Scholar
• Bruckert E, Gagne C, Gaudet D, et al. Homozygous familial hypercholesterolemia: novel therapy with ezetimibe [abstract]. Atherosclerosis 2002;3:81
   Google Scholar
• Dobs AS, Guyton JR, McClusky D, et al. Coadministration of ezetimibe with simvastatin. J Am Coll Cardiol 2003;41:227A
   PubMed Web of Science ®Google Scholar
• Efrati S, Averbukh M, Dishy V, et al. The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers. Eur J Clin Pharmacol 2007;63:113-21
   PubMed Web of Science ®Google Scholar
• Feldman T, Koren M, Insull W, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004;93:1481-6
   PubMed Web of Science ®Google Scholar
• Masana L, Mata P, Gagné C, et al. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Clin Ther 2005;27:174-84
   PubMed Web of Science ®Google Scholar
• Meaney A, Ceballos G, Asbun J, et al. The vytorin on carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol 2009;49:838-47
   PubMed Web of Science ®Google Scholar
• Roeters van Lennep HWO, Liem AH, Dunselman PH, et al. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr Med Res Opin 2008;24:685-94
   PubMed Web of Science ®Google Scholar
• Strony J, Yang B, Hanson ME, et al. Long-term safety and tolerability of ezetimibe coadministered with simvastatin in hypercholesterolemic patients: A randomized, 12-month double-blind extension study. Curr Med Res Opin 2008;24:3149-57
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Lipka LJ, Sager PT, et al. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract 2004;58:653-8
   PubMed Web of Science ®Google Scholar
• Conard SE, Bays HE, Leiter LA, et al. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol 2008;102:1489-94
   PubMed Web of Science ®Google Scholar
• Leiter LA, Bays H, Conard S, et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol 2008;102:1495-501
   PubMed Web of Science ®Google Scholar
• Stein E, Stender S, Mata P, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004;148:447-55
   PubMed Web of Science ®Google Scholar
• Zieve F, Wenger NK, Ben YO, et al. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in patients > or =65 years of age (from the ZETia in the ELDerly (ZETELD) study). Am J Cardiol 2010;105:656-63
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Blazing MA, King TR, et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93:1487-94
   PubMed Web of Science ®Google Scholar
• Barrios V, Amabile N, Paganelli F, et al. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int J Clin Pract 2005;59:1377-86
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45
   PubMed Web of Science ®Google Scholar